↑ 疾患リストへ ← 戻る

 283. 後天性赤芽球癆 [臨床試験数:12,薬物数:25(DrugBank:17),標的遺伝子数:15,標的パスウェイ数:84] 

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03966053September 13, 201930 September 2019The Use of Trifluoperazine in Transfusion Dependent DBAPhase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan AnemiaDiamond Blackfan Anemia;Pure Red Cell AplasiaDrug: TrifluoperazineAdrianna VlachosRecruiting18 Years65 YearsAll24Phase 1/Phase 2United States
2NCT03918265April 10, 201929 April 2019Tacrolimus Treatment for Refractory Autoimmune CytopeniaTacrolimus Treatment for Refractory Autoimmune CytopeniaAutoimmune Hemolytic Anemia;Pure Red Cell Aplasia;Evans SyndromeDrug: TacrolimusPeking Union Medical College HospitalNot recruiting18 Years80 YearsAll80Phase 4China
3NCT03540472June 10, 201811 June 2018Tacrolimus Treatment for Refractory PRCATacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective StudyPure Red Cell AplasiaDrug: tacrolimusPeking Union Medical College HospitalRecruiting18 Years80 YearsAll30Phase 4China
4NCT03364764January 201816 December 2017Sirolimus Treatment for Refractory PRCASirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective StudyPure Red Cell AplasiaDrug: SirolimusBing HanRecruiting18 Years80 YearsAll30Phase 4China
5NCT03333486December 7, 201725 June 2018Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerA Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem CellsAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Acute Leukemia in Remission;Acute Lymphoblastic Leukemia;Acute Myeloid Leukemia;Acute Myeloid Leukemia With FLT3/ITD Mutation;Acute Myeloid Leukemia With Gene Mutations;Aplastic Anemia;B-Cell Non-Hodgkin Lymphoma;CD40 Ligand Deficiency;Chronic Granulomatous Disease;Chronic Leukemia in Remission;Chronic Lymphocytic Leukemia;Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Chronic Myelomonocytic Leukemia;Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Congenital Amegakaryocytic Thrombocytopenia;Congenital Neutropenia;Congenital Pure Red Cell Aplasia;Glanzmann Thrombasthenia;Immunodeficiency Syndrome;Myelodysplastic Syndrome;Myelofibrosis;Myeloproliferative Neoplasm;Paroxysmal Nocturnal Hemoglobinuria;Plasma Cell Myeloma;Polycythemia Vera;Recurrent Non-Hodgkin Lymphoma;Refractory Non-Hodgkin Lymphoma;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndrome;Severe Aplastic Anemia;Shwachman-Diamond Syndrome;Sickle Cell Disease;T-Cell Non-Hodgkin Lymphoma;Thalassemia;Waldenstrom Macroglobulinemia;Wiskott-Aldrich SyndromeDrug: Cyclophosphamide;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Procedure: Peripheral Blood Stem Cell Transplantation;Radiation: Total-Body IrradiationRoswell Park Cancer InstituteNational Cancer Institute (NCI)Recruiting1 Year75 YearsAll58Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01362595June 201330 September 2019Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan AnemiaThe Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan AnemiaDiamond Blackfan Anemia;Blackfan Diamond Syndrome;DBA;Congenital Hypoplastic Anemia;Pure Red Cell AplasiaDrug: leucineNorthwell HealthNot recruiting2 YearsN/AAll50Phase 1/Phase 2United States
7NCT01288131January 200919 February 2015Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) TreatmentRandomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and PrednisoloneAnti-r-HuEpo Associated PRCA SubjectsDrug: Cyclosporine combine with mycophenolate mofetil;Drug: Cyclophosphamide + predChulalongkorn UniversityNot recruiting18 Years60 YearsBoth8Phase 3Thailand
8EUCTR2005-004944-30-GB23/02/200631 August 2015A Phase 2 study of AF37702 Injection for anemia in patients with pure red cell aplasia.An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease - AFX01-06Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease
MedDRA version: 18.0 Level: PT Classification code 10002965 Term: Aplasia pure red cell System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: AF37702 Injection
Product Code: AF37702, Hematide
Pharmaceutical Form: Solution for injection
INN or Proposed INN: peginesatide
CAS Number: 1185870-58-9
Current Sponsor code: AF37702
Other descriptive name: Hematide, peginesatide
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Product Name: AF37702 Injection
Product Code: AF37702, Hematide
Pharmaceutical Form: Solution for injection
INN or Proposed INN: peginesatide
CAS Number: 1185870-58-9
Current Sponsor code: AF37702
Other descriptive name: Hematide, peginesatide
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 12-
Takeda Development Centre Europe LtdNot RecruitingFemale: yes
Male: yes
40Phase 2Germany;United Kingdom
9NCT00229619September 200519 October 2017Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaA Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaAnemia, Aplastic;Red-Cell Aplasia, Pure;Anemia, Diamond-BlackfanDrug: RituximabNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting2 YearsN/AAll11Phase 2United States
10NCT00006055March 200019 February 2015Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesPurpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu ArteritisDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell TransplantationFairview University Medical CenterNot recruiting1 Year55 YearsBoth10N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00001962November 199919 October 2017A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow FailureA Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaAplastic Anemia;Pure Red Cell Aplasia;Diamond Blackfan AnemiaDrug: DaclizumabNeal Young, M.D.Not recruiting2 YearsN/AAll100Phase 2United States
12NCT00004143September 199919 October 2017Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure SyndromesAllogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure SyndromesSickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell AplasiaDrug: Campath, Chemo and/or TBI Allo SCTDavid Rizzieri, MDNot recruiting18 YearsN/AAll2Phase 2United States

先頭へ